Conditions: Autism Spectrum Disorder Pervasive Developmental Disorder ASD PDD
Keywords: Autism Spectrum Disorders Pervasive Developmental Disorder ASD PDD Oxytocin Syntocinon Social Impairment Treatment
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 7
Healthy volunteers: no

Brief summary:
This study is an 8-week pilot trial with oxytocin nasal spray (Syntocinon) as a treatment for social impairment in children and adults with high functioning autism spectrum disorders (ASD). The investigators hypothesize that oxytocin will be safe, tolerable, and effective in improving social deficits in individuals with ASD.

Detailed description:

Arms:
arm 1: Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks. arm 2: Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.

Interventions: intervention 1: Intranasal Oxytocin
Intervention descriptions: intervention 1: This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).

Protocol document:
Prot_SAP_000.pdf: 
OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
1 
 
Study Protocol:  
A Pilot Study of Oxytocin for the Treatment of Social Impairment in Individuals 
with High Functioning Autism Spectrum Disorder  
 
Gagan Joshi, MD 
Massachusetts General Hospital 
Clinical and Research Program in Pediatric Psychopharmacology 
 
IND Number: 133492 
 
Version Date: CR 2 RtR 1, submitted to the IRB: 05/01/2019  
Last Modified: 05/01/2019  
 
 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
2 
1. BACKGROUND AND SIGNIFICANCE 
 
Autism Spectrum Disorder (ASD) is estimated to affect up to 1.5% of youth in the 
general population (Autism and Developmental Disabilities Monitoring Network 
Surveillance Year 2010). Deficits in social interaction are the central feature of ASD, 
and to date there is no pharmacological treatment available to address it.  
Oxytocin (OT) is a pro-social neuropeptide hormone that has been reported to have 
a powerful role in affiliative behaviors in both humans and other mammals. OT plays a 
role in the formation of trust in humans (e.g. Kirsch et al., 2005, Baumgartner et al., 
2008), in promoting social behavior in other animals (Williams et al., 1994), and has 
been shown to improve ‘mind-reading’ (ToM) performance in healthy people (Domes et 
al., 2007). This hormone is of particular interest because several gene-linkage studies in 
different cultural cohorts have shown an association between several single-nucleotide 
polymorphisms associated with OT and risk for ASD (Jacob et al., 2007; Liu et al., 
2010). Acute OT administration improved accurate recognition of affect in speech in 
ASD (Hollander et al., 2007), decreased repetitive behaviors (Hollander et al, 2003), 
and increased the proportion of time that ASD participants spent looking at the eyes in 
static pictures of faces (Andari et al., 2010). In animal models, OT receptor knockout 
mice show social recognition deficits (Ferguson et al., 2000; Takayanagi et al., 2005) 
and, OT administration into the central amygdala appears to reverse these deficits 
(Ferguson et al., 2001). 
Recent studies investigating chronic intranasal oxytocin administration suggest that 
the treatment is safe and well tolerated amongst youths and adults with ASD (Guastella 
et al., 2015; Tachibana M et al., 2013; Anagnostou et al., 2012). In a total 5-month trial 
(8-week randomized-controlled trial [RCT] followed by 3-month open-label trial [OLT]) of 
daily administration of oxytocin (24 IU BID) was well tolerated by adolescent males with 
ASD (N=26; ages 12-18) (Guastella et al., 2015). A 6-week RCT that examined the 
safety and efficacy of daily administration of intranasal oxytocin (24 IU BID) in adults 
with ASD (N=19; ages 19-46) reported no significant, serious, or treatment-limiting 
adverse events (Anagnostou et al., 2012). Results of such recent research indicate that 
chronic oxytocin administration in youth and adults with ASD is both safe as well as 
promising and that future studies are warranted to continue to evaluate the efficacy of 
chronic oxytocin treatment for social impairment amongst individuals with ASD.  
 
 
2. SPECIFIC AIMS 
This proposal seeks to examine the short-term efficacy and tolerability of intranasal 
oxytocin for the treatment of social impairment in youths and adults with high-
functioning ASD (HF-ASD).  We will be conducting a prospective, open label 8-week 
pilot trial with oxytocin nasal spray (Syntocinon). Based on the literature and our 
previous work, we hypothesize that oxytocin will be safe, tolerable, and effective in 
improving social deficits in individuals with ASD. We propose to enroll 30 youth 12-17 
years of age and 30 adults 18-55 years of age of both sexes with HF-ASD. 
 
 
3. LENGTH OF STUDY 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
3 
Total duration of participation from enrollment to completion in this 8-week OLT of 
OT may take up to 11 weeks (allowing up to three weeks from date of consent to 
schedule and complete the baseline (week 0) visit). Subjects will be assessed on 
measures of efficacy and safety at the baseline (week 0), midpoint (week 4), and 
endpoint visits (at completion (week 8) or early termination).  
 
4. SOURCE OF SUBJECTS 
In order to achieve the goal of exposing 40 subjects to the study medication, we 
anticipate to consent up to 60 individuals with HF-ASD. Participants will be recruited 
from the referral pool of existing ASD patients within the Clinical and Research 
Programs in Pediatric Psychopharmacology and Adult ADHD, the Division of Child and 
Adolescent Psychiatry, as well as the Bressler MGPO practice at MGH.  
If a potential subject’s clinician ascertains that the patient has an interest in study 
participation, the clinician will offer contact information for the study coordinator to the 
patient and their parents/guardian(s). The patient and their parent/guardian can then 
contact the study coordinator for more information on the trial. Further, the subject’s 
clinician may also provide the contact information of interested, prospective participants 
to the study coordinator so that (s)he may recruit and communicate with perspective 
subjects via telephone calls and email. Any email communication with subjects will be 
done using encrypted email (i.e. “Send Secure”), unless the subjects opt to receive non-
encrypted email. The benefits on encrypted emails will be explained to subjects. All 
participants, upon attaining the consent and/or assent by a clinician other than the 
patient’s treating clinician, will undergo standard screening procedures. Participants 
who meet the study inclusion criteria and no study exclusion criteria will be offered to 
initiate the OT trial. 
Subjects who have completed a previous medication trial in our program may be 
eligible to participate in this study, as described in the Study Design section. Other 
medical records on a subject will not be used at any point during this study. 
 
5. SUBJECT ENROLLMENT 
Informed consent/assent will be obtained prior to administering study related 
procedures and drug treatment. The informed consent and assent documents will be 
used to explain, in simple terms, the risks and benefits of study participation to the 
subject and, if the subject is between the ages of 12 and 17, their parent/guardian. 
Subjects ages 12-17 will provide written assent. Subjects ages 14-17 will sign the same 
consent form as the parent, while subjects ages 12-13 will sign a separate assent form. 
If a subject turns 18 years old during the course of this study, he/she will be asked to 
sign the consent form again as an adult before continuing with the study. If the subject 
refuses to provide written consent after attaining majority status, he/she will be 
discontinued from the study. For subjects over 18, informed consent for self-
participation will be obtained. The nature of the study will be fully explained to the 
subject and their parent/guardian by a study clinician other than the subject’s treating 
physician, who is either the principal investigator or a co-investigator. The subject and 
their parent/guardian will be encouraged to ask questions pertaining to their 
participation in the study and the subject and their parent/guardian may take as much 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
4 
time as they feel necessary to consider their participation in the study and to consult 
with family members or their physician. Participation in this study is entirely voluntary, 
and the subjects and/or their caretaker may withdraw from the study at any time for any 
reason. The IRB-approved informed consent/assent documents will be signed and 
dated by the subject and the physician obtaining consent. 
 
6. SUBJECT SELECTION CRITERIA 
A. Inclusion Criteria 
1. Male and females between 12 and 55 years of age.  
2. Meets DSM-5 diagnostic criteria for ASD as established by clinical diagnostic 
interview and the MGH ASD Symptom Checklist.  
3. At least moderate severity of ASD impairment as measured by a raw score of 
≥85 on the SRS. 
4. Participants and their parent/guardian must be able to speak and understand 
English sufficiently to comprehend the nature of the study and to allow for the 
completion of all study procedures required per protocol. 
5. Subjects and their parent/guardian must be considered reliable reporters. They 
must understand the nature of the study and must sign an IRB-approved 
informed consent form before initiation of any study procedures. Subjects and 
their parent/guardian must have a level of understanding sufficient to 
communicate with the investigator and study coordinator, and to cooperate with 
all tests and examinations required by the protocol. 
6. Each subject and their parent/guardian must understand the nature of the study 
and provide written informed assent/consent. 
7. Subjects with mood, anxiety, or disruptive behavior disorders will be allowed to 
participate in the study provided they do not meet any exclusionary criteria. 
8. Subject must be willing to restrict concomitant usage of any intranasal 
medications.  
9. If the subject is sexually active, he/she must agree to use an acceptable form of 
birth control during the study.  These include: 
o Abstinence (no sexual contact) 
o A barrier method (diaphragm plus spermicide or a condom plus 
spermicide) in addition to one of the following methods: 
§ Consistent use of an approved birth control pill 
§ Birth control patch 
§ Injected contraceptives 
§ Intrauterine device (IUD) 
 
B. Exclusion Criteria 
1. Impaired intellectual functioning and/or impaired spoken language. 
2. Clinically unstable psychiatric conditions or any serious medical illness, 
which will be assessed by study clinicians during the psychiatric 
interview and medical history review. If the clinical assessment suggests 
a psychiatric or medical condition demanding acute clinical attention, 
then the subject will be excluded from participating in the trial.  


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
5 
3. Pregnant or nursing females.  
4. Known hypersensitivity to oxytocin. 
5. Severe allergies or multiple adverse drug reactions. 
6. A non-responder or history of intolerance to oxytocin, after treatment at adequate 
doses as determined by the clinician.   
7. Subjects with significant nasal pathology (including atrophic rhinitis, recurrent 
nose bleeds, and history of hypophysectomy). 
8. Clinically abnormal baseline laboratory values falling significantly outside of the 
standard reference ranges for a basic metabolic screen that jeopardize safe 
participation in the trial as determined by study clinician. 
9. Investigator and his/her immediate family defined as the investigator’s spouse, 
parent, child, grandparent, or grandchild. 
10. Currently enrolled or recently participated (within the past 6 months) in a clinical 
trial of intranasal oxytocin. 
 
7. DESIGN 
 
All data will be collected and entered into REDCap, an electronic data capture 
system that streamlines data collection and ensures data integrity. REDCap software 
allows researchers to design and implement study surveys electronically for collecting, 
storing, retrieving, and manipulating data. 
Participants/guardians and/or research staff will enter survey responses into 
electronic assessment forms using computers at the research site. The responses will 
then be transmitted securely via an encrypted connection and stored in a secured 
database. Electronic data capture eliminates the need for subsequent data entry by staff, 
thus minimizing human error. However, in the event that REDCap is malfunctioning, 
study staff will print all study instruments and study data will be collected in paper form.  
Primary outcome measure of efficacy will be reduction in ASD symptom severity as 
measured by change from baseline raw score on the SRS. Responders will be defined 
as ≥30% reduction in SRS raw score. Safety and tolerability will be assessed by the 
monitoring of treatment-emergent adverse events by the participant’s treating clinician. 
In the event that a participant’s treating clinician is unavailable to assess safety and 
tolerability for a particular study visit, the participant will be scheduled with another study 
clinician who will conduct the safety and tolerability monitoring. 
 
 
Dosing 
 
Test Dose: Participants found eligible to participate in the trial will receive a test dose of 
oxytocin at the baseline visit (week 0). The test dose of 24 IU will be administered 
intranasally by the study clinician in order to: 1) demonstrate to patients and their 
parents the proper administration technique of the study medication; and 2) ensure that 
subject is able to tolerate intranasal administration. Participants who tolerate the single 
dose of oxytocin will participate in the 8-week chronic administration oxytocin trial if they 
so choose (see details on pages 8 & 9). 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
6 
 
8-week OLT: Over the course of the 8-week study, participants will be evaluated at 4 
week intervals. First at the baseline visit, at the midpoint study visit (week 4, and at the 
endpoint study visit (at completion [week 8] or upon early termination). At each visit, 
assessment measures of safety and efficacy will be administered and subjects will be 
evaluated for response to the treatment and adverse events. 
 
The oxytocin will be administered in twice daily divided dosages with a total daily 
dose of 48 IU/day. A 24 IU administration of the oxytocin will be administered in the 
morning and afternoon to achieve the 48 IU daily dose. Each spray (puff) contains 4 IU 
of oxytocin, thus a full 24 IU dose will consist of 3 puffs per nostril. There will be an 
option for lowering the dose based on tolerability and response to oxytocin per clinician 
judgment. Study clinicians will be available 24 hours a day/7 days a week by pager in 
the event of any adverse reactions. 
 
To assess and ensure drug accountability and compliance, study medication will be 
returned at every visit. Study staff will remind subjects to return all study medication 
bottles when contacting subjects to confirm their next study visit. Additionally, study staff 
will emphasize the importance of returning study medication when dispensing the 
medication to subjects. Because the study medication is in the form of a nasal spray, it 
is difficult to physically calculate medication compliance. Subjects or their 
parent/guardian will be asked to keep a medication log to record the amount of nasal 
spray administered, as well as the time of each administration. Subjects will be 
reminded to bring this medication log with them to each study visit along with their study 
medication.  
 
Concomitant Medications/Treatments 
At each study visit, subjects will be assessed for the use of concomitant medication. 
The guidelines for use of concomitant medications/treatments during the study are as 
follows: 
• Concomitant administration of carboprost, dinoprostone vaginal gel/insert, ephedra, 
ephedrine, or direct sympathomimetics will not be allowed. 
• Subjects may maintain treatment with psychotropic medications throughout the 
study, provided that they have been on a stable regimen for at least 3 weeks prior to 
baseline.  
• Non-pharmacological treatments such as supportive individual, family, or group 
therapy will be permitted provided they were in place for at least 3 weeks prior to 
study enrollment and remain unchanged during the course of the trial.  
 
 
Screening Process (Week 99) 
Before any participant can start the study, the study physician will discuss the details 
of the study with the participant and their parent/guardian. No study procedures will be 
initiated before the participant agrees to participation and provides written consent in the 
case of an adult (ages 18-55) or the participant and the participant’s parent/guardian 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
7 
agrees to participation and provides written consent in the case of a minor (ages 12-17) 
as well as written assent for participants ages 12-13 years. 
 
The screening process, including the process of attaining informed consent/assent, 
will take 1-2 hours in total and includes the following components: 
 
• Subjects will meet with a study clinician for a psychiatric interview and review of 
medical history. 
• The clinician will complete the MGH ASD Symptom Checklist. If this form has been 
completed by a clinician within the past year prior to a subject’s entrance into this 
study, we will use the previously collected data so as to not burden the subject with 
redundant time commitments.  
• Female participants of childbearing potential will complete a urine pregnancy test. If 
a participant has a positive pregnancy test, she will not be able to take part in the 
study. The study physician will inform the participant and discuss the clinically 
appropriate course of action. The decision whether to inform the participant’s 
parent/guardian of these results will be made by the study physician based on the 
participant’s age and maturity level. The participant will be offered 3 follow-up visits.  
• Participants will be required to give a urine sample to test for illicit drugs. If the 
results are positive for drug(s), subjects will not be allowed to participate in this trial.       
• About 1 tablespoon of blood will be drawn for laboratory tests. Clinical laboratory 
testing will consist of a basic metabolic panel (electrolytes, liver function tests, and 
glucose). Vital signs (blood pressure, heart rate, height, and weight) will be 
collected. The basic metabolic panel consists of the following tests: Na, K, Cl, CO2 
(bicarb), BUN, Glucose, Creatinine, and Calcium. 
• For subjects ages 12-17: 
o We will ask the subject’s parent/guardian to fill out a questionnaire about 
the subject’s ASD symptoms (SRS-2 School Age) as well as a brief 
demographic questionnaire collecting information regarding 
socioeconomic status and history of head injury or trauma. These 
questionnaires will take approximately 25 minutes to complete.  
• For subjects ages 18-55: 
o We will ask subjects to fill out a questionnaire about their ASD symptoms 
(SRS-2 Adult Self-Report) as well as a brief demographic questionnaire 
collecting information regarding socioeconomic status and history of head 
injury or trauma. These questionnaires will take approximately 25 minutes 
to complete 
o Optional: If an informant for the participant is available, (s)he will be 
asked to fill out a scale about the subject’s severity of autism spectrum 
symptoms (SRS-2 Adult Informant). This will take approximately 20 
minutes to complete. 
 
If a subject and/or informant has completed any of the above scales (SRS-2 School 
Age, SRS-2 Adult Self-Report or the demographic questionnaire) for another study 
within the Clinical and Research Programs in Pediatric Psychopharmacology and Adult 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
8 
ADHD (or through his/her clinical care within these programs), the Division of Child and 
Adolescent Psychiatry, or through the Bressler MGPO practice at MGH within the past 6 
months prior to a subject’s entrance into this study, they will not be asked to repeat 
them at the week 99 screening visit. We will use the previously collected study 
assessment data so as to not burden the subject with redundant time commitments. 
However, the study clinician will review the interval time period to assess for clinically 
significant medical or psychiatric history to ensure that the subject meets appropriate 
study entrance criteria.    
 
 
Office Study Visits (Weeks 0, 4, and 8) 
Study visits will have a visit window of +/- 5 days to facilitate scheduling.  
 
 
During study visits: 
• A study doctor will ask the participant questions about the participant’s ASD 
symptoms as well as general and mental health. 
• The study physician will ask if the participant is having any side effects, and if they 
have taken any other medications during the previous week (see Table I for details). 
• We will measure participant’s blood pressure, heart rate, and weight. 
• We will ask the participant for a urine sample in order to test for illegal drugs. We will 
do this at Weeks 4 and 8. 
• We will ask for a urine sample to test for pregnancy for female participants of 
childbearing potential. We will do this at Weeks 4 and 8. 
• During the final study visit (Week 8), we will obtain blood for a basic metabolic 
screen. The total amount of blood drawn during this study is about 2 tablespoons. 
• For participants ages 12-17: 
o At weeks 4 and 8, we will ask the participant’s parent/guardian to fill out the 
SRS-2 School Age form. This will take about 15 minutes.  
o At week 0 and week 8, we will also ask the participant’s parent/guardian to fill 
out questionnaires about the subject’s emotional functioning (CBCL) and 
quality of life (PQ-LES-Q). These questionnaires will take approximately 20 
minutes to complete.  
o At weeks 0, 4, and 8, we will ask the participant’s parent/guardian to fill out 
the MGH Social-Emotional Competence Scale (Informant-Rated Measure) 
(MGH-SECS-I). This will take about 10 minutes. 
• For participants ages 18-55: 
o At weeks 4 and 8, we will ask participants to fill out the SRS-2 Adult Self-
Report. This will take approximately 15 minutes. 
o At week 0 and week 8, we will also ask participants to fill out questionnaires 
about their emotional functioning (ASR), and quality of life (Q-LES-Q). These 
questionnaires will take approximately 20 minutes to complete.  
o At week 4 and 8, if an informant for the participant is available, (s)he will be 
asked to fill out a questionnaire about the subject’s severity of autism 
spectrum symptoms (SRS-2 Adult Informant). This will take approximately 15 
minutes to complete. 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
9 
o At weeks 0 and 8, if an informant for the participant is available, (s)he will be 
asked to fill out a questionnaire about the subject’s emotional functioning 
(ABCL). This will take approximately 10 minutes to complete. 
o At weeks 0, 4, & 8, if an informant for the participant is available, (s)he will be 
asked to fill out the MGH-SECS-I. This will take approximately 10 minutes to 
complete. 
 
Phone Study Visit (Week 2) 
This study visit will have a visit window of +/- 5 days to facilitate scheduling.  
 
During this study visit: 
• A study doctor will call the participant and ask them questions about the participant’s 
ASD symptoms as well as general and mental health. 
• The study physician will ask if the participant is having any side effects, and if they 
have taken any other medications during the previous week (see Table I for details). 
 
 
Study Discontinuation 
A participant or parent/guardian may withdraw consent at any time for any reason 
(e.g., lack of efficacy, adverse events, etc.). A subject may be withdrawn from the study 
at any time if any of the following conditions are met: 
• Subjects who experience intolerable adverse effects, and/or clinically significant 
laboratory values inconsistent with continuation in the study as determined by the PI. 
• Worsening of psychiatric or medical illness as determined per clinical assessment or 
as reflected by Clinical Global Improvement score of 6 (Much worse) or 7 (Very 
much worse) for 2 visits in a row.  
• Unstable psychiatric condition that clinically requires 1) treatment with prohibited 
concomitant psychotropic medications or 2) subjects requiring inpatient psychiatric 
admission. 
• Emergent suicidality in the opinion of the investigator or as evidenced by a “yes” to 
questions 4 and/or 5 of Columbia-Suicide Severity Rating Scale (C-SSRS) within the 
last 1 month. 
• Active substance abuse 
• Pregnancy 
• Allergic drug reaction 
• Non-compliance (less than 70% compliance for 2 visits or longer based on parent 
report) 
• Failure to keep study appointments for more than 2 consecutive visits without 
justification 
• Clinical judgment of the investigator 
• Withdrawal of consent 
 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
10 
Those subjects who terminate study participation before the completion of the study 
will be asked to complete all tasks scheduled to take place on the final study visit at the 
time of study discontinuation. 
Subjects who fail to keep study appointments or are non-compliant based on 
parent/self report (less than 70% compliance for two weeks or longer) may be dropped 
from the study. These study subjects will resume their clinical care with their respective 
treating clinician.   
Subjects recruited from the Principal Investigator or Co-Investigator’s own patient 
pool who drop out of the study prior to completion of the study will resume their care 
with their respective treating clinicians. If a subject chooses to drop out of the study, his 
or her clinical care now and in the future will not be affected. At study completion, 
subjects who complete the study will also resume their care with their respective 
treating clinicians.  
If study participation is discontinued for safety reasons, participants will be offered 
three follow-up clinical visits, allowing adequate time for appropriate psychiatric referrals 
to treaters in their communities. 
 
 
8. ASSESSMENTS (See Table I for an assessment schedule) 
 
Study Rating Scales 
 
Participants ages 12-17:  
(Administered at screening evaluation) 
• Social Responsiveness Scale: Second Edition School Age (SRS-2 School Age) is a 
65-item rating scale completed by parent or guardian that is used to measure the 
severity of autism spectrum symptoms as they occur in natural settings (Constantino 
& Gruber, 2012). 
• Demographic Questionnaire is a brief demographic questionnaire administered to 
subject’s parent/guardian to estimate socioeconomic status, as well as collect 
information about any educational accommodations and past head injuries and/or 
trauma (Hollingshead, 1975). 
(Administered at baseline [week 0] and final study visits [week 8/drop visit])  
• Child Behavior Checklist (CBCL) is a parent-report questionnaire that evaluates 
maladaptive behavioral and emotional problems, both internalizing and externalizing, 
in children ages 6-18 (Achenbach, 2001). 
• Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) is a 
self/parent/guardian-report measure that assesses quality of life from the subject’s 
perspective (Endicott et al., 2006). Subjects or parents/guardians are instructed to 
consider each item and indicate their response on a scale of 1-5.  
(Administered at midpoint [week 4] and final study visits [week 8/drop visit]) 
• Social Responsiveness Scale: Second Edition School Age (SRS-2 School Age) is a 
65-item rating scale completed by parent or guardian that is used to measure the 
severity of autism spectrum symptoms as they occur in natural settings (Constantino 
& Gruber, 2012). 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
11 
(Administered at baseline [week 0], midpoint [week 4], and final study visits [week 
8/drop visit])  
• MGH Social-Emotional Competence Scale (Informant-Rated Measure) (MGH-
SECS-I) is a 37-item scale that asks informants to rate subjects on their social 
competence and abilities on a Likert scale from 0 to 6. 
 
Participants ages 18-55:  
(Administered at screening evaluation) 
• Social Responsiveness Scale-Second Edition Self-Report (SRS-2 Adult Self-
Report): a 65-item rating scale completed by subjects that is used to measure the 
severity of autism spectrum symptoms as they occur in natural settings (Constantino 
& Gruber, 2012). 
• Demographic Questionnaire is a brief demographic questionnaire administered to the 
subject to estimate socioeconomic status, as well as collect information about any 
educational accommodations and past head injuries and/or trauma (Hollingshead, 
1975). 
(Administered at baseline [week 0] and final study visits [week 8/drop visit])  
• Adult Self Report (ASR) is a self-rated questionnaire that evaluates maladaptive 
behavioral and emotional problems, both internalizing and externalizing, in adults 
ages 18-59 (Achenbach, 2003). 
• Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q): a 16-item 
questionnaire to evaluate the degree of enjoyment and satisfaction experienced in 
eight areas of daily functioning (Endicott, Nee et al. 1993). 
• Adult Behavior Checklist (ABCL) is an informant-rated assessment of adult behavior, 
social competence, and substance use (Achenbach & Rescorla, 2003) 
(Administered at screening evaluation, and midpoint [week 4] and final study visits [week 
8/drop visit]) 
• Social Responsiveness Scale-Second Edition Informant-Report (SRS-2 Adult 
Informant): a 65-item rating scale completed by parents/caregivers that is used to 
measure the severity of autism spectrum symptoms of the subjects as they occur in 
natural settings (Constantino & Gruber, 2012). 
(Administered at baseline [week 0], midpoint [week 4], and final study visits [week 
8/drop visit])  
• MGH Social-Emotional Competence Scale (Informant-Rated Measure) (MGH-
SECS-I): is a 37-item scale that asks informants to rate subjects on their social 
competence and abilities on a Likert scale from 0 to 6.  
 
Clinician-Rated: 
Diagnostic 
• MGH Autism Spectrum Disorder DSM-5 Diagnostic Symptom Checklist (MGH-ASD-
SCL): The range and severity of subjects’ ASD symptoms will be assessed with the 
clinician-administered MGH-ASD-SCL. This screening instrument adopted items 
from DSM-5 diagnostic criteria for ASD and assesses for the individual core domains 
and associated features of ASD.  


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
12 
Safety 
• Clinician-Rated Treatment Emergent Adverse Events Log (CTAE): to record any 
spontaneous adverse health events experienced during the study, along with 
duration, severity, cause, treatment, and outcome. 
• Concomitant Medications Log: to record additional medications taken during the 
study. 
Rating Scales 
• Columbia-Suicide Severity Rating Scale (C-SSRS): to assess previous suicidality of 
a subject at screening as well as any new instances of suicidality during the study. 
• Clinical Global Impression Scale (CGI): The CGI is a measure of illness severity, 
improvement, and efficacy of treatment. The score for severity ranges from 1 
(normal, not at all ill) to 7 (among the most extremely ill subjects). Improvement 
ranges from 1 (very much improved) to 7 (very much worse). And lastly, the 
effectiveness index measures to what extent the subject is experiencing therapeutic 
effects as well as the level of adverse events they are experiencing. The CGI scale 
will be used for the assessment of ASD (NIMH, 1985). 
 
9. DATA ANALYSIS 
 
Statistical Analysis 
Considering this study’s open-label single group design, we will rely on comparisons 
of participants’ performances at baseline (Week 0) prior to the initiation of treatment 
relative to their scores at the last assessment (Week 8 or drop). Thus, statistics for 
paired samples will be utilized. This design largely protects against the bias introduced 
by confounding factors. That is, since the same participants are tested on two 
occasions, all static confounding factors are perfectly balanced, and can have no impact 
on the findings. Bias can still result from time-varying factors that are not associated 
with the outcomes, but we are confident that any such factors will have a minimal 
impact on this study, considering the duration of the trial. Specifically, we will employ 
Wilcoxon signed rank tests for continuous or discrete outcome measures, and 
McNemar’s test for binary outcomes. These tests are free from assumptions regarding 
the distribution of the outcome variables, which is appropriate since the scales we are 
proposing to utilize are not considered to have Gaussian distributions, and will not be 
amenable to parametric methods. 
 
10. SAFETY 
Consistent with good clinical practice, safety will be monitored at each study visit by 
a subject’s assigned clinician. This clinician will be available 24 hours a day by page. 
The Principal Investigator will supervise all study activities including ratings, reported 
adverse events, laboratory tests, and vital signs. All procedures have been designed to 
minimize subject discomfort, and no subject will be asked to engage in research 
procedures not outlined in the consent form.  
If a subject is withdrawn from the study due to adverse events, lack of response, or 
as a decision by the clinician, they will be offered open treatment for three months, 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
13 
giving adequate time for appropriate psychiatric care to be arranged.  
Blood Draw  
A topical anesthetic cream (EMLA) will be offered to subjects before blood draws. 
The dose of EMLA cream will not exceed administration guidelines based on subject 
age and weight. Subjects with sensitivity to local topical anesthetics will not receive 
EMLA cream.  If an infection does occur, it will be treated. 
Study Medication 
Safety will be monitored through treatment-emergent adverse events and measuring 
change in vital signs through laboratory analyses. Subjects will be monitored for 
adverse events at each visit. All adverse events will be recorded. A subject may be 
dropped from the study or dosage may be decreased and timing of medication changed 
at any time due to adverse events. All adverse events will be reported to the PHRC 
according to PHRC guidelines. All concomitant medications will be assessed at every 
study visit. At screening, subjects with contraindicated concomitant medications will be 
given the option of discontinuing such medications or will be withdrawn from the study. 
 
11. CONFIDENTIALITY 
All research-related records initiated as a result of a subject’s participation in this 
study that reveal the subject’s identity will remain confidential except as may be 
required by law. While the results of the clinical laboratory blood testing will become part 
of a subject’s Massachusetts General Hospital medical record, they will not link the 
subject to participation in any research. Subjects will only be contacted regarding future 
studies if they indicate that they are interested in being contacted by initialing in the 
specific section of the consent form. 
 
12. RISKS AND DISCOMFORTS 
Syntocinon nasal spray is not FDA-approved for any indication. Syntocinon injection is 
indicated for medical (rather than elective) induction of labor. As was mentioned in the 
Background and Significance section, in recent clinical trials involving intranasal 
oxytocin administration in humans, the risks of oxytocin have been mild and rare. A 
review of the safety, side effects, and case-by-case reactions to intranasal oxytocin 
examined 38 randomized controlled trials in which 8% of participants met diagnostic 
criteria for a developmental or mental health disorder (MacDonald et al., 2011). The 
review corroborated the aforementioned recent research findings as side effects of 
intranasal oxytocin were mild—reported side effects included increased 
calmness/euphoria, feeling more comfortable or having more energy, light headedness, 
drowsiness and/or headache, nasal irritation, and dry mouth/throat. The researchers 
concluded that the evidence showed that intranasal oxytocin produced no reliable side 
effects and was not associated with adverse outcomes when delivered in doses of 18-
40 IU for short-term use. 
 
Chronic administration of oxytocin (24 IU BID) was well tolerated by adolescent males 
with ASD (N=26; ages 12-18) (Guastella et al., 2015). The number of side effects 
reported did not differ between placebo and oxytocin groups at any point during the trial. 
No serious adverse events resulted from oxytocin treatment compared to placebo. In a 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
14 
long-term open label study in which youth males (N=8; ages 10-14)  received daily 
intransal oxytocin in a stepwise increased dosage manner every 2 months (8, 16, 24 
IU/dose), all participants reported no side effects (Tachibana M et al., 2013). Side 
effects in this trial were assessed by monitoring blood pressure and examining urine 
and blood samples. A 6-week RCT that examined the safety and efficacy of daily 
administration of intranasal oxytocin (24 IU BID) in adults with ASD (N=19; ages 19-46) 
reported no significant, serious, or treatment-limiting adverse events (Anagnostou et al., 
2012). There were no significant differences observed between oxytocin and placebo 
groups in any blood results and no abnormal electrocardiograms were reported. Results 
of such recent research indicate that chronic oxytocin administration in youth and adults 
with ASD is both safe as well as promising and that future studies are warranted to 
continue to evaluate the efficacy of chronic oxytocin treatment for social impairment 
amongst individuals with ASD.  
 
 
Frequent Adverse Events 
The most frequently observed adverse reactions to oxytocin nasal spray 
(Syntocinon) are abnormal uterine contractions, headache, nausea and dermatitis 
allergic. The frequency of nasal discomfort associated with administration of Syntocinon 
is not known. Less frequently observed adverse reactions include mild to moderate 
increases in irritiability, mild fatigue, headache, leg shaking, and increased energy 
(Anagnostou et al., 2012). The evidence to date suggests that administering oxytocin 
intranasally does not increase the risks associated with the drug product.   
All participants will be closely monitored for serious adverse reactions. All serious 
unexpected adverse events will be reported to the Partners Human Research 
Committee as stipulated by PHRC regulations. 
 
Other Adverse Events 
Problems and side effects not listed above and not known at this time could occur. 
Subjects will be informed of any newly discovered risks as investigators come to learn 
of such knowledge, if applicable. 
When blood is drawn, some discomfort may occur. Bruising and/or bleeding at the 
needle site may occur. Occasionally a person feels faint. Rarely, an infection may 
develop. If an infection does occur, it can be treated. A topical anesthetic cream (EMLA) 
will be offered to subjects to numb the skin where blood will be drawn if subjects prefer. 
For all subjects and their parent/guardian, there is a risk of inconvenience and 
potential discomfort for filling out rating scales and questionnaires. All of the information 
about participants will be treated confidentially. Subjects and their parent/guardian can 
choose not to answer any questions that they do not feel comfortable answering.  
Adverse events and unanticipated problems will be reported to the PHRC according 
to current guidelines. We will follow and adhere to all guidelines as defined and outlined 
on the Partners Human Research Committee web site: 
(http://healthcare.partners.org/phsirb/adverse_events.htm). 
 
 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
15 
13. POTENTIAL BENEFITS 
There may be no direct benefit to subjects participating in this study. Participants 
may potentially benefit by experiencing improvement in social impairments and by 
gaining knowfledge about ASD.  
 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
16 
Table I. Study Schema 
 
 
 
 
99
0
2
4
8
Consent/Assent
X
Procedures
Test Dose
X
Blood Draw
X
X
Vital Signs (weight, BP, pulse)
X
X
X
X
Height
X
Urine Drug Screen
X
X
X
Urine Pregnancy Test (WOCBP)
X
X
X
Clinician Rated Scales
Psych Eval & Med History
X
CTAE
X
X
X
X
Concomitant Medications
X
X
X
X
X
MGH ASD Checklist
X
CGI-ASD-SI
X
X
X
X
CGI-ASD-SC
X
X
X
X
CGI-ASD-M
X
X
X
X
CGI-ASD
X
X
X
X
C-SSRS
X
X
X
Medication Log Review
X
X
X
Parent/Guardian Rated Scales 
Demograhic Questionnaire
X
SRS-2 School Age
X
X
X
CBCL
X
X
PQ-LES-Q
X
X
MGH-SECS-I
X
X
X
Self Rated Scales (Ages 18-55)
Demograhic Questionnaire
X
SRS-2 Adult Self-Report
X
X
X
ASR
X
X
Q-LES-Q
X
X
Optional Informant Scale (Ages 18-
MGH-SECS-I
X
X
X
ABCL
X
X
SRS-2 Adult Informant
X
X
X


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
17 
REFERENCES  
 
Achenbach T. (2001). Manual for the Child Behavior Checklist/6-18. Burlington, VT: 
University of Vermont Department of Psychiatry. 
Achenbach T, Rescorla L. (2003) Manual for the ASEBA Adult Forms & 
Profiles.Burlington, VT: University of Vermont, Research Center for Children, 
Youth, & Families. 
Anagnostou, E, Soorya L, Chaplin W, Bartz, J, Halpern D, Wasserman S., Wang AT, 
Pepa L, Tanel N, Kushki A, Hollander E. (2012). Intranasal oxytocin versus 
placebo in the treatment of adults with autism spectrum disorders: a randomized 
controlled trial. Molecular Autism. 3(16): 1-9. PMCID: PMC3917666. 
Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A. (2010). Promoting 
social behavior with oxytocin in high-functioning autism 
spectrum disorders. 
Proc Natl Acad Sci USA. 107(9):4389-94. PMID: 
20160081. 
Autism and Developmental Disabilities Monitoring Network Surveillance Year 2010. 
(2014). Prevalence of autism spectrum disorders among children aged 8 years—
Autism and Developmental Disabilities Monitoring Network, 11 sites, United 
States, 
2010. MMWR Surveill Summ. 63(2):1-21. PMID: 24670961. 
Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E. (2008).
 
Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. 
Neuron. 58(4):639-50. PMID: 18498743. 
Constantino JN & Gruber CP. (2012). Social Responsiveness Scale, Second
 
Edition (SRS-2). Torrance, CA: Western Psychological Services. 
Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. (2007). Oxytocin improves 
“mind-reading” in humans. Biol Psychiatry. 61(6):731-3. PMID: 
17137561. 
Endicott, J., Nee, J., Harrison, W., Blumenthal, R. (1993). Quality of life enjoyment and 
satisfaction questionnaire: a new measure. Pscyhophamacol Bull, 29(2), 321-
326.  
Endicott J, Nee J, Yang R, Wohlberg C. (2006). Pediatric Quality of Life 
Enjoyment 
and Satisfaction Questionnaire (PQ-LES-Q): reliability and 
validity. J Am Acad 
Child Adolesc Psychiatry. 45(4): 401-7. PMID: 16601644. 
Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. (2000). 
Social 
amnesia in mice lacking the oxytocin gene. Nat Genet. 25(3):284-8. PMID: 
10888874. 
Ferguson JN, Aldag JM, Insel TR, Young LJ. (2001). Oxytocin in the medial
 
amygdala is essential for social recognition in the mouse. J Neurosci.
 
21(20):8278-85. PMID: 11588199. 
Guastella AJ, Gray KM, Rinehart NJ, Alvares GA, Tonge BJ, Hickie IB, Keating CM, 
Cacciotti-Saija C, Einfeld SL. (2015). The effects of a course of intranasal 
oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: 
a randomized controlled trial. J Child Psychol Psychiatry. 56(4): 444-452. PMID: 
25087908 
Hollander E, Novotny S, Hanratty M, Yaffe R, Decaria CM, Aronowitz BR,  Mosovich S. 
(2003). Oxytocin infusion reduces repetitive behaviors in 
adults with autistic 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
18 
and Asperger’s disorders. Neuropsychopharmacology. 
28(1):193-8. PMID: 
12496956. 
Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, et al. (2007).
 
Oxytocin increases retention of social cognition in autism. Biol Psychiatry.
 
61(4):498-503. PMID: 16904652. 
Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, et al.
 
(2012). A double-blind placebo-controlled trial of fluoxetine for repetitive
 
behaviors and global severity in adult autism spectrum disorders. Am J
 
Psychiatry. 169(3):292-9. PMID: 22193531. 
Hollingshead, A.B. (1975). Four factor index of social status.  
Jacob S, Brune CW, Carter CS, Leventhal BL, Lord C, Cook EH Jr. (2007).
 
Association of the oxytocin receptor gene (OXTR) in Caucasian children
 
and adolescents with autism. Neurosci Lett. 417(1):6-9. PMID: 17383819. 
Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, et al. (2005). Oxytocin
 
modulates neural circuitry for social cognition and fear in humans. J
 
Neurosci. 25(49):11489-93. PMID: 16339042. 
Liu X, Kawamura Y, Shimada T, Otowa T, Koishi S, Sugiyama T, et al. (2010). 
Association of the oxytocin receptor (OXTR) gene polymorphisms with 
autism 
spectrum disorder (ASD) in the Japanese population. J Hum Genet. 55(3):137-
41. PMID: 20094064. 
MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, & Cauchi AJ. (2011). A 
review of safety, side-effects and subjective reactions to intranasal oxytocin in 
human research. Psychoneuroendocrinology. 36(8): 1114-26. PMID: 21429671 
McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. (1996). A 
double-blind, placebo-controlled study of fluvoxamine in adults 
with autistic 
disorder. Arch Gen Psychiatry. 53(11):1001-8. PMID: 8911223. 
National Institute of Mental Health: CGI (Clinical Global Impression) Scale—NIMH. 
Psychopharmacol Bull 21:839–844, 1985. 
Research Units on Pediatric Psychopharmacology Autism Network. (2002).
 
Risperidone in children with autism and serious behavioral problems. N 
Engl J 
Med. 347(5):314-21. PMID: 12151468. 
Research Units on Pediatric Psychopharmacology Autism Network. (2005).
 
Randomized, controlled, crossover trial of methylphenidate in pervasive
 
developmental disorders with hyperactivity. Arch Gen 
Psychiatry.62(11):1266-74. PMID: 16275814. 
Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. (2004). Risperidone 
in the treatment of disruptive behavioral symptoms in children 
with autistic 
and other pervasive developmental disorders. Pediatrics. 
114(5):e634-41. 
PMID: 15492353. 
Tachibana M, Kagitani-Shimono K, Mohri I, Yamamoto T, Sanefuji W, Nakamura A, 
Oishi M, Kimura T, Onaka T, Ozono K, Taniike M. (2013). Long-term 
administration of intranasal oxytocin is a safe and promising therapy for early 
adolescent boys with autism spectrum disorders. J Child Adolesc 
Psychopharmacol. 23(2): 123-7. PMID: 23480321. 


OT Pilot for Social Impairment in Individuals with ASD 
Version: CR 1 RtR 1, 06/06/2018 
Last Modified: 06/06/2018 
 
 
19 
Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, et al.
 
(2005). Pervasive social deficits, but normal parturition, in oxytocin 
 
receptor-deficient mice. Proc Natl Acad Sci USA. 102(44):16096-101.
 
PMID: 16249339. 
Williams JR, Insel TR, Harbaugh CR, Carter CS. (1994). Oxytocin administered
 
centrally facilitates formation of a partner preference in female prairie
 
voles (Microtus ochrogaster). J Neuroendocrinol. 6(33):247-50. PMID:
 
7920590.